Dupuytren’s contracture treated with collagenase Clostridium histolyticum

  • Received 22.02.2023
  • Revised 28.04.2023
  • Accepted 30.05.2023
  • 703 Views
  • Retrieved from Vol. 9, No. 1, 2023
  • Pages 39-46

Treatment of Dupuytren’s contracture improves the quality of life of patients, but standard open fasciectomy surgery is traumatic and requires long-term rehabilitation. The study aimed to determine whether injectable treatment with collagenase preparations was effective in comparison with open fasciectomy. Forty patients were examined. Of these, 15 were treated with Clostridium histolyticum collagenase preparations (the main group), and 25 underwent limited fasciectomy (the control group). In 11 (73.3%) patients of the main group, restoration of mobility of the affected joints was achieved after the first injection, in 3 (20%) – after the second, and in 1 (6.7%) – after the third. Patients in the main group remained able to work after treatment and did not require rehabilitation; the function of the upper limb was fully restored on the day of intervention. During the observation period, 12 (80%) patients in the main group were concerned about dry skin at the intervention site, and 5 (33.3%) patients were concerned about itching and discolouration of the skin at the intervention site. In 25 (100%) patients of the control group, joint mobility was fully restored. The ability to use the hand after surgery in patients of the control group was limited for 6 (4.5; 10) days. All patients in the control group required rehabilitation to relieve stiffness and restore the functional capabilities of the hand. The period of disability in these patients lasted 16 (12; 24.5) days. 11 (44%) patients had complaints of pain or discomfort in the intervention area during the follow-up, and 24 (96%) patients were bothered by itching. Satisfaction with the choice of treatment method in the main group was more frequent compared to the control group. Relapses during the observation period were absent in both groups. Thus, the efficacy of Clostridium histolyticum collagenase preparations are comparable to the results of surgical treatment. Minimally invasive treatment is optimal for patients with mild disease, as well as for those who have a low risk of contracture recurrence. The results of this study can be useful for surgeons when choosing the optimal method of treating Dupuytren’s contracture

palmar fibromatosis; minimally invasive intervention; hand surgery; open fasciectomy; clinical trial; patient management

https://doi.org/10.61751/ijmmr.2413-6077.2023.1.39

[1] Salari N, Heydari M, Hassanabadi M, Kazeminia M, Farshchian N, Niaparast M, et al. The worldwide prevalence of the Dupuytren disease: A comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15:495. DOI: 10.1186/s13018-020-01999-7

[2] Layton T, Nanchahal J. Recent advances in the understanding of Dupuytren's disease. F1000Res. 2019;8:231. DOI: 10.12688/f1000research.17779.1

[3] Ruettermann M, Hermann RM, Khatib-Chahidi K, Werker PMN. Dupuytren's disease – etiology and treatment. Dtsch Arztebl Int. 2021;118(46):781–88. DOI: 10.3238/arztebl.m2021.0325

[4] Jovanovic NA, Smilic L, Smilic T, Markovic-Jovanovic SR, Mitic J, Filimonovic J, et al. Quality of metabolic control, serum potassium, and aging are the major determinants of severity of musculoskeletal disorders in hospitalized diabetic patients. Int J Diabetes Dev Ctries. 2020;40:296–2. DOI: 10.1007/s13410-019-00776-5

[5] Murínová L, Perečinský S, Jančová A, Murín P, Legáth Ľ. Is Dupuytren's disease an occupational illness? Occup Med. 2021;71(1):28–33. DOI: 10.1093/occmed/kqaa211

[6] Rydberg M, Zimmerman M, Persson Löfgren J, Gottsäter A, Nilsson PM, Melander O, Dahlin LB. Metabolic factors and the risk of Dupuytren’s disease: Data from 30,000 individuals followed for over 20 years. Sci Rep. 2021;11:14669. DOI: 10.1038/s41598-021-94025-7

[7] Wang Z, Wang Z, Yan Z, Xu Z, Gao A. Smoking, alcohol consumption and risk of Dupuytren’s disease: A Mendelian randomization study. BMC Med Genomics. 2023;16:212. DOI: 10.1186/s12920-023-01650-4

[8] Sanjuan-Cervero R. Current role of the collagenase Clostridium histolyticum in Dupuytren’s disease treatment. Ir J Med Sci. 2020;189:529–34. DOI: 10.1007/s11845-019-02127-z

[9] Dupuytren’s contracture [Internet]. [cited 2023 Nov 23]. Availiable from: https://bestpractice.bmj.com/topics/en-gb/983

[10] International ethical guidelines for health-related research involving humans [Internet]. Geneva: CIOMS; 2016 [cited 2023 Nov 23]. 122 p. Availiable from: https://doi.org/10.56759/rgxl7405

[11] Brazzelli M, Cruickshank M, Tassie E, McNamee P, Robertson C, Elders A, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: Systematic review and economic evaluation. Health Technol Assess. 2015;19(90). DOI:10.3310/hta19900

[12] Sandler AB, Scanaliato JP, Dennis T, Gonzalez Trevizo GA, Raiciulescu S, Nesti L, Dunn JC. Treatment of dupuytren's contracture with collagenase: A systematic review. Hand. 2022;17(5):815–24. DOI:10.1177/1558944720974119

[13] Sanjuan-Cerveró R, Carrera-Hueso FJ, Vazquez-Ferreiro P, Ramon-Barrios MA. Efficacy and adverse effects of collagenase use in the treatment of Dupuytren's disease: A meta-analysis. Bone Joint J. 2018;100-B(1):73–80. DOI: 10.1302/0301-620X.100B1.BJJ-2017-0463.R1

[14] Soreide E, Murad MH, Denbeigh JM, Lewallen EA, Dudakovic A, Nordsletten L, et al. Treatment of Dupuytren's contracture: A systematic review. Bone Joint J. 2018;100-B(9):1138–45. DOI: 10.1302/0301-620X.100B9.BJJ-2017-1194.R2

[15] Obed D, Salim M, Schlottmann F, Bingoel AS, Panayi AC, Dastagir K, et al. Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren's contracture: a network meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2022;23(1):939. DOI: 10.1186/s12891-022-05894-6

[16] Cooper TB, Poonit K, Yao C, Jin Z, Zheng J, Yan H. The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren's contracture management: A meta-analysis. J Orthop Surg. 2020;28(2):2309499020921747. DOI: 10.1177/2309499020921747

[17] Liechti R, Merky DN, Sutter D, Ipaktchi R, Vögelin E. Collagenase clostridium histolyticum injection versus limited fasciectomy for the treatment of Dupuytren's disease: A systematic review and meta-analysis of comparative studies. Arch Orthop Trauma Surg. 2023. DOI: 10.1007/s00402-023-05004-8

[18] Nann S, Kovoor J, Fowler J, Kieu J, Gupta A, Hewitt J, et al. Surgical management of dupuytren disease: A systematic review and network meta-analyses. Hand. 2023;15589447231174175. DOI: 10.1177/15589447231174175

[19] Fitzpatrick AV, Moltaji S, Ramji M, Martin S. Cost analyses of fasciectomy, needle aponeurotomy, and collagenase injection for treatment of dupuytren’s contracture: A systematic review. Plast Surg. 2021;29(4):257–64. DOI: 10.1177/2292550320963111

[20] Wong CR, Huynh MNQ, Fageeh R, McRae MC. Outcomes of management of recurrent dupuytren contracture: A systematic review and meta-analysis. Hand. 2022;17(6):1104–13. DOI: 10.1177/1558944721994220

[21] Hindocha S. Risk factors, disease associations, and dupuytren diathesis. Hand Clin. 2018;34(3):307–14. DOI: 10.1016/j.hcl.2018.03.002

[22] Geoghegan L, Man J, Jain A, Price A, Gibbons E, Jerosch-Herold C, et al. Factors associated with the development, progression, and outcome of dupuytren disease treatment: A systematic review. Plast Reconstr Surg. 2021;148(5):753–63. DOI: 10.1097/PRS.0000000000008420